
Feb 27 (Reuters) - Merck & Co Inc MRK.N:
KEYTRUDA® (PEMBROLIZUMAB) PLUS PACLITAXEL WITH OR WITHOUT BEVACIZUMAB SIGNIFICANTLY IMPROVED KEY SECONDARY ENDPOINT OF OVERALL SURVIVAL (OS) VERSUS PACLITAXEL WITH OR WITHOUT BEVACIZUMAB IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER